Opus Genetics, Inc. Variable Lease, Cost
Opus Genetics, Inc. (IRD) reported Variable Lease, Cost of $3.52 thousand for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-10-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2020-10-29
- Opus Genetics, Inc. variable lease, cost for the quarter ending 2020-09-30 was $3.52K, a 23.39% increase year-over-year.
- Opus Genetics, Inc. variable lease, cost for the quarter ending 2020-06-30 was $6.11K, a 8.24% decline year-over-year.
- Opus Genetics, Inc. variable lease, cost for the quarter ending 2020-03-31 was $5.69K, a 64.45% decline year-over-year.
- Opus Genetics, Inc. variable lease, cost for the quarter ending 2019-12-31 was $3.23K.
- Opus Genetics, Inc. variable lease, cost for fiscal 2019 was $28.75K.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2020-09-30 | $3.52K 10-Q · filed 2020-10-29 | $9.63K derived: sum of 2 quarters · filed 2020-10-29 | $15.33K 10-Q · filed 2020-10-29 | $18.55K derived: sum of 4 quarters · filed 2020-10-29 |
| 2020-06-30 | $6.11K 10-Q · filed 2020-08-14 | $11.80K 10-Q · filed 2020-08-14 | $15.03K derived: sum of 3 quarters · filed 2020-08-14 | $17.89K derived: sum of 4 quarters · filed 2020-10-29 |
| 2020-03-31 | $5.69K 10-Q · filed 2020-05-07 | $8.92K derived: sum of 2 quarters · filed 2020-05-07 | $11.78K derived: sum of 3 quarters · filed 2020-10-29 | $18.43K derived: sum of 4 quarters · filed 2020-10-29 |
| 2019-12-31 | $3.23K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $6.08K derived: sum of 2 quarters · filed 2020-10-29 | $12.74K derived: sum of 3 quarters · filed 2020-10-29 | $28.75K 10-K · filed 2020-02-21 |
| 2019-09-30 | $2.86K 10-Q · filed 2020-10-29 | $9.52K derived: sum of 2 quarters · filed 2020-10-29 | $25.53K 10-Q · filed 2020-10-29 | |
| 2019-06-30 | $6.66K 10-Q · filed 2020-08-14 | $22.67K 10-Q · filed 2020-08-14 | ||
| 2019-03-31 | $16.01K 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |